Key result
AGT M235T heterozygous genotype linked to lower amlodipine response in ~28% of hypertensive patients.
Why the study?
Response to amlodipine varies among individuals with hypertension, and the angiotensinogen M235T genotype's influence on this response had not been established.
Does the AGT M235T genotype influence the blood pressure response to amlodipine in patients with essential hypertension?
Does the AGT M235T genotype influence the blood pressure response to amlodipine in patients with essential hypertension?
The AGT M235T heterozygous genotype and younger age are associated with a reduced blood pressure response to amlodipine in Jordanian patients with essential hypertension.
Answers are grounded in this paper and cite their sources.
May warrant AGT M235T genotyping before amlodipine; extends prior pharmacogenetic data but remains hypothesis-generating.
Introduction: Amlodipine, a calcium channel blocker, is widely used to treat hyperten-sion, but its effectiveness varies among individuals. Clinicians have observed this variability, and previous research suggests that the Angiotensinogen (AGT) M235T genotype influences response to antihypertensive drugs like valsartan. This study investigates the association between the AGT M235T genetic variant and non-genetic anthropometric factors, and the response to amlodipine in essential hypertensive patients at the University of Jordan Hospital. Methods: A cohort of 46 unrelated Arabic Jordanian patients with essential hypertension was en-rolled. Baseline systolic and diastolic blood pressure (BP) readings were recorded before initiating 5 mg amlodipine, with follow-up measurements taken after one month. AGT M235T genotyping was performed using PCR-RFLP, and non-genetic data were obtained from hospital records. Results: It was found that 28.3% of the tested patients did not respond to amlodipine. The hetero-zygous AGT M235T genotype showed a significantly (p < 0.05, t-test) lower reduction in the BP compared to wild-type carriers, and its frequency was significantly higher (p < 0.05, ꭙ2 test) among the non-responders to amlodipine. In addition, the average age of the non-responders (41.5±10.3 years) was significantly (p < 0.05, t-test) lower than that of responders (47±10 years) to amlodipine. Discussion: The heterozygous AGT M235T genotype partially explained inter-individual varia-tion in response to amlodipine among hypertensive patients of Jordanian Arab origin. Conclusion: It can be concluded that the AGT M235T heterozygous genotype is linked to reduced amlodipine response, while older age is associated with a higher efficacy. However, further multi-center studies with larger cohorts are needed to confirm these findings. conclusion: The AGT M235T heterozygous genotype is linked to reduced amlodipine response, while older age is associated with greater drug efficacy. However, further multi-central studies with larger cohorts are needed to confirm these findings.
No takes yet. Share an insight, caveat, or question.
Jarrar et al. (2026) studied this question. The AGT M235T heterozygous genotype was associated with a significantly lower response to amlodipine in 28.3% of hypertensive patients.
Synapse has enriched 10 related papers. Consider them for comparative context: